{"altmetric_id":26488749,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":10},"news":{"unique_users_count":6,"unique_users":["nasdaq","bioportfolio","pr_newswire","ktre","2_news","device_space"],"posts_count":6},"blogs":{"unique_users_count":1,"unique_users":[60247],"posts_count":1},"twitter":{"unique_users_count":2,"unique_users":["ThihaSwe_dr","raj_psyc"],"posts_count":2},"facebook":{"unique_users_count":1,"unique_users":["450103581726698"],"posts_count":1}},"selected_quotes":["Targeted pharmacogenetic-guided treatment of patients with depression anxiety: Encouraging RCT findings"],"citation":{"altmetric_jid":"4f6fa4f63cf058f610002ee6","authors":["Bradley, Paul","Shiekh, Michael","Mehra, Vishaal","Vrbicky, Keith","Layle, Stacey","Olson, Marilyn C.","Maciel, Alejandra","Cullors, Ali","Garces, Jorge A.","Lukowiak, Andrew A.","Paul Bradley","Michael Shiekh","Vishaal Mehra","Keith Vrbicky","Stacey Layle","Marilyn C. Olson","Alejandra Maciel","Ali Cullors","Jorge A. Garces","Andrew A. Lukowiak"],"doi":"10.1016\/j.jpsychires.2017.09.024","first_seen_on":"2017-09-23T21:49:40+00:00","issns":["0022-3956","00223956"],"journal":"Journal of Psychiatric Research","last_mentioned_on":1506434012,"links":["https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=6&redirect=http%3A%2F%2Fwww.journalofpsychiatricresearch.com%2Farticle%2FS0022-3956%2817%2930718-5%2Ffulltext%3Frss%3Dyes&code=piat-site","http:\/\/www.journalofpsychiatricresearch.com\/article\/S0022-3956(17)30718-5\/fulltext?rss=yes","http:\/\/www.journalofpsychiatricresearch.com\/article\/S0022-3956%2817%2930718-5\/fulltext#.WcexXgWKgDQ.twitter","http:\/\/dx.doi.org\/10.1016\/j.jpsychires.2017.09.024","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=3&redirect=http:\/\/www.journalofpsychiatricresearch.com\/article\/S0022-3956(17)30718-5\/fulltext?rss=yes&code=piat-site"],"pubdate":"2017-09-01T00:00:00+00:00","publisher":"Elsevier BV","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"},{"name":"Psychology And Cognitive Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Neuroscience"],"title":"Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility","type":"article"},"altmetric_score":{"score":54.83,"score_history":{"1y":54.83,"6m":54.83,"3m":54.83,"1m":54.83,"1w":30,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":54.83},"context_for_score":{"all":{"total_number_of_other_articles":8462170,"mean":7.1084920520889,"rank":174792,"this_scored_higher_than_pct":97,"this_scored_higher_than":8287546,"rank_type":"exact","sample_size":8462170,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":120662,"mean":11.703837992392,"rank":5127,"this_scored_higher_than_pct":95,"this_scored_higher_than":115535,"rank_type":"exact","sample_size":120662,"percentile":95},"this_journal":{"total_number_of_other_articles":1575,"mean":7.5009695044473,"rank":36,"this_scored_higher_than_pct":97,"this_scored_higher_than":1539,"rank_type":"exact","sample_size":1575,"percentile":97},"similar_age_this_journal_3m":{"total_number_of_other_articles":33,"mean":14.7751875,"rank":2,"this_scored_higher_than_pct":93,"this_scored_higher_than":31,"rank_type":"exact","sample_size":33,"percentile":93}}},"demographics":{"poster_types":{"member_of_the_public":1,"practitioner":1},"users":{"twitter":{"cohorts":{"Members of the public":1,"Practitioners (doctors, other healthcare professionals)":1}}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/ThihaSwe_dr\/statuses\/911708886654177280","license":"gnip","citation_ids":[26488749],"posted_on":"2017-09-23T21:48:31+00:00","author":{"name":"Psychiatry Updates","url":"https:\/\/www.facebook.com\/PsychiatryUpdates.by.DrThihaSwe","image":"https:\/\/pbs.twimg.com\/profile_images\/3471096253\/6b7bd3fc313986902cd1574474364bae_normal.jpeg","description":"[RSS Updates from Psychiatry Journals globally, plus some mental health related news] \/ Should follow only if you are interested in Mental Health","id_on_source":"ThihaSwe_dr","tweeter_id":"1259166031","geo":{"lt":null,"ln":null},"followers":1002},"tweet_id":"911708886654177280"},{"url":"http:\/\/twitter.com\/raj_psyc\/statuses\/911943926713606144","license":"gnip","citation_ids":[26488749],"posted_on":"2017-09-24T13:22:29+00:00","author":{"name":"Rajesh Mohan","image":"https:\/\/pbs.twimg.com\/profile_images\/906420504969351168\/bCTa3IFo_normal.jpg","description":"Rehabilitation Psychiatrist, SLaM NHS FT; Equality, QI & sustainability in NHS. Right services@Right time","id_on_source":"raj_psyc","tweeter_id":"842278113727922177","geo":{"lt":null,"ln":null},"followers":1076},"tweet_id":"911943926713606144"}],"blogs":[{"title":"Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility","url":"http:\/\/ifp.nyu.edu\/2017\/journal-article-abstracts\/improved-efficacy-with-targeted-pharmacogenetic-guided-treatment-of-patients-with-depression-and-anxiety-a-randomized-clinical-trial-demonstrating-clinical-utility\/","license":"public","citation_ids":[26488749],"posted_on":"2017-09-24T00:09:00+00:00","summary":"&hellip;\nRead article here:\nImproved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility\nThe post Improved efficacy with targeted pharmacogenetic-guided","author":{"name":"information for practice","url":"http:\/\/ifp.nyu.edu\/","description":"news, new scholarship &amp; more from around the world"}}],"news":[{"title":"AltheaDx Prospective, Randomized Controlled Clinical Trial Demonstrates Significant Improvements in the Treatment of Depression and Anxiety over Standard of Care","url":"http:\/\/ct.moreover.com\/?a=31960281633&p=1pl&v=1&x=u-tSR0ZWbaF9eC5INbwYPQ","license":"public","citation_ids":[26488749],"posted_on":"2017-09-26T01:00:00+00:00","summary":"SAN DIEGO, Sept. 26, 2017 \/PRNewswire\/ -- AltheaDx, Inc. (\"AltheaDx\" or the \"Company\"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, announced today that the results from its clinical trial\u2026","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"AltheaDx Prospective, Randomized Controlled Clinical Trial Demonstrates Significant Improvements in the Treatment of Depression and Anxiety over Standard of Care","url":"http:\/\/ct.moreover.com\/?a=31960354475&p=1pl&v=1&x=FeOKT-bwnKYfAdZAZje8yA","license":"public","citation_ids":[26488749],"posted_on":"2017-09-26T09:07:02+00:00","summary":"SAN DIEGO, Sept. 26, 2017 \/PRNewswire\/ -- AltheaDx, Inc. (\"AltheaDx\" or the \"Company\"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, announced today that the results from its clinical trial\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"AltheaDx Prospective, Randomized Controlled Clinical Trial Demonstrates Significant Improvements in the Treatment of Depression and Anxiety over Standard of Care","url":"http:\/\/ct.moreover.com\/?a=31960359655&p=1pl&v=1&x=jYJNnySA2JZ1dxUCaCxfAg","license":"public","citation_ids":[26488749],"posted_on":"2017-09-26T13:00:00+00:00","summary":"SAN DIEGO, Sept. 26, 2017 \/PRNewswire\/ --. (\"AltheaDx\" or the \"Company\"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, announced today that the results from its clinical trial have been\u2026","author":{"name":"PR Newswire","url":"http:\/\/www.prnewswire.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/545\/normal\/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}},{"title":"AltheaDx Prospective, Randomized Controlled Clinical Trial Demonstrates Significant Improvements in the Treatment of Depression and Anxiety over Standard of Care","url":"http:\/\/ct.moreover.com\/?a=31960727756&p=1pl&v=1&x=ob5yKAjZwNsn9GwfRNJzXw","license":"public","citation_ids":[26488749],"posted_on":"2017-09-26T13:53:32+00:00","summary":"Information contained on this page is provided by an independent third-party content provider.","author":{"name":"KTRE","url":"http:\/\/www.ktre.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/705\/normal\/Screen_Shot_2016-01-26_at_15.04.21.png?1453820750"}},{"title":"AltheaDx Prospective, Randomized Controlled Clinical Trial Demonstrates Significant Improvements in the Treatment of Depression and Anxiety over Standard of Care","url":"http:\/\/ct.moreover.com\/?a=31960816148&p=1pl&v=1&x=szx0DyFbF5SB1qjazNpewg","license":"public","citation_ids":[26488749],"posted_on":"2017-09-26T13:51:00+00:00","summary":"Information contained on this page is provided by an independent third-party content provider.","author":{"name":"2 News","url":"http:\/\/www.ktvn.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/654\/normal\/Screen_Shot_2016-01-26_at_12.05.19.png?1453809947"}},{"title":"AltheaDx Prospective, Randomized Controlled Clinical Trial Demonstrates Significant Improvements In The Treatment Of Depression And Anxiety Over Standard Of Care","url":"http:\/\/www.devicespace.com\/news_story.aspx?StoryID=470601&full=1","license":"public","citation_ids":[26488749],"posted_on":"2017-09-26T00:00:00+00:00","summary":"SAN DIEGO, Sept. 26, 2017 \/PRNewswire\/ -- AltheaDx, Inc. (\"AltheaDx\" or the \"Company\"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, announced today that the results from its clinical trial\u2026","author":{"name":"Device Space","url":"http:\/\/www.devicespace.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/840\/normal\/Screen_Shot_2016-02-02_at_15.36.30.png?1454427403"}}],"facebook":[{"title":"secure.jbs.elsevierhealth.com","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1633153903421654&id=450103581726698","license":"public","citation_ids":[26488749],"posted_on":"2017-09-23T21:48:26+00:00","summary":"Journal of Psychiatric Research\nImproved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility The objective of this study was to evaluate the effect of p","author":{"name":"Psychiatry - Updates by Dr Thiha Swe","url":"https:\/\/www.facebook.com\/450103581726698","facebook_wall_name":"Psychiatry - Updates by Dr Thiha Swe","image":"https:\/\/graph.facebook.com\/450103581726698\/picture","id_on_source":"450103581726698"}}]}}